COMP <GO>
BSX vs LLY // OPERATING MARGIN
Boston Scientific Corporation (NYSE) VS. Eli Lilly and Company (NYSE) • 15-METRIC TALLY: BSX 4
— LLY 11
▲ OPERATING MARGIN LEADER: LLY
LAST: $41.98 (-1.66%) • MKT CAP: $61.87B
operating-margins
18.00%
LAST: $1,417.54 (+3.19%) • MKT CAP: $1.33T
operating-margins
40.21%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (BSX VS. LLY)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | BSX | LLY | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 69.00% | 83.64% | -14.64 | LLY | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 9.20% | 32.36% | -23.16 | LLY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 15.8x | 36.4x | -20.62 | BSX | /valuation <GO> |
| Free Cash Flow Yield | 5.91% | 2.30% | +3.61 | BSX | /fcf-yield <GO> |
| Operating Margin ACTIVE | 18.00% | 40.21% | -22.21 | LLY | /operating-margins <GO> |
| Net Profit Margin | 14.00% | 31.90% | -17.90 | LLY | /net-margins <GO> |
| Revenue Growth (YoY) | 19.90% | 45.51% | -25.61 | LLY | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.49% | -0.49 | LLY | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 2.77 | 9.29 | -6.52 | LLY | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 9/9 | -1.00 | LLY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 6.90% | 6.77% | +0.13 | LLY | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 38.8 | 77.9 | -39.11 | LLY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.99 | 0.51 | +0.48 | BSX | /macro-sensitivity <GO> |
| Forward P/E Multiple | 18.5x | 26.3x | -7.75 | BSX | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $61.87B | $1.33T | -$1.27T | LLY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | BSX REV | LLY REV | BSX GROSS % | LLY GROSS % | BSX FCF | LLY FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $20.07B | $65.18B | 69.0% | 83.0% | $3.66B | $16.81B |
| FY 2024 | $16.75B | $45.04B | 68.6% | 81.3% | $2.65B | $8.82B |
| FY 2023 | $14.24B | $34.12B | 44.0% | 79.3% | $1.86B | $4.24B |
| FY 2022 | — | $28.54B | — | 76.8% | — | $7.59B |
| FY 2021 | — | $28.32B | — | 74.2% | — | $7.37B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
BSX // BETA 0.99
LLY // BETA 0.51